Tunitas Therapeutics is a privately held biopharmaceutical company that is poised to develop unique and precisely targeted protein therapeutics that will dramatically change the lives of allergy sufferers. With Tunitas’ proteins, patients receive a treatment regimen in their allergist’s office that will alter the natural course of their disease, providing a therapeutic option with long-lasting benefit. Building on the long-established precedent of allergy immunotherapy, the company’s allergen-specific vaccines focus on an entirely novel approach to an unmet medical need — food allergy, providing long-term relief for the 3% of adults and 6-8% of children with this condition. The regimen is expected to be safer, more effective and able to be completed in a fraction of the time of conventional allergy immunotherapy.